These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19828926)

  • 1. [Genetic polymorphism of CYP-450 in drug development].
    Nonen S; Azuma J
    Nihon Yakurigaku Zasshi; 2009 Oct; 134(4):212-5. PubMed ID: 19828926
    [No Abstract]   [Full Text] [Related]  

  • 2. Applications of CYP450 testing in the clinical setting.
    Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
    Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacogenetics].
    Hach I; Kirch W
    Praxis (Bern 1994); 2008 Oct; 97(21):1127-9. PubMed ID: 18951351
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus.
    Semiz S; Dujic T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Marc J; Causevic A
    Bosn J Basic Med Sci; 2010 Nov; 10(4):287-91. PubMed ID: 21108610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
    Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine.
    Wang Z; Wang S; Huang M; Hu H; Yu L; Zeng S
    Chirality; 2014 Mar; 26(3):166-73. PubMed ID: 24464553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
    Seeringer A; Kirchheiner J
    Internist (Berl); 2008 Jul; 49(7):877-83. PubMed ID: 18551264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.
    Lee LS; Nafziger AN; Bertino JS
    Clin Pharmacol Ther; 2005 Jul; 78(1):1-6. PubMed ID: 16003286
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
    Hicks JK; Swen JJ; Thorn CF; Sangkuhl K; Kharasch ED; Ellingrod VL; Skaar TC; Müller DJ; Gaedigk A; Stingl JC;
    Clin Pharmacol Ther; 2013 May; 93(5):402-8. PubMed ID: 23486447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
    Sistonen J; Fuselli S; Palo JU; Chauhan N; Padh H; Sajantila A
    Pharmacogenet Genomics; 2009 Feb; 19(2):170-9. PubMed ID: 19151603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.
    Müller DJ; Kekin I; Kao AC; Brandl EJ
    Int Rev Psychiatry; 2013 Oct; 25(5):554-71. PubMed ID: 24151801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug metabolism and variability among patients in drug response.
    Wilkinson GR
    N Engl J Med; 2005 May; 352(21):2211-21. PubMed ID: 15917386
    [No Abstract]   [Full Text] [Related]  

  • 18. [Single nucleotide polymorphism and novel drug discovery].
    Kato R
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):303-8. PubMed ID: 12610884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
    Ingelman-Sundberg M; Sim SC
    Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.
    Bahar MA; Setiawan D; Hak E; Wilffert B
    Pharmacogenomics; 2017 May; 18(7):701-739. PubMed ID: 28480783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.